Urotensin II receptor expression in patients with ulcerative colitis: a pilot study

被引:6
|
作者
Gravina, Antonietta G. [1 ]
Dallio, Marcello [1 ]
Tuccillo, Concetta [1 ]
Martorano, Marco [2 ]
Abenavoli, Ludovico [3 ]
Luzza, Francesco [3 ]
Stiuso, Paola [1 ]
Lama, Stefania [1 ]
Grieco, Paolo [4 ]
Merlino, Francesco [4 ]
Caraglia, Michele [1 ]
Loguercio, Carmelina [1 ]
Federico, Alessandro [1 ]
机构
[1] Luigi Vanvitelli Univ Campania, Dept Precis Med, Via Pansini 5, I-80131 Naples, Italy
[2] Immacolata Hosp, Unit Gastroenterol & Endoscopy, Salerno, Italy
[3] Magna Grccia Univ, Dept Hlth Sci, Catanzaro, Italy
[4] Univ Naples Federico II, Dept Pharm, Naples, Italy
关键词
Urotensins; Colitis; ulcerative; Pilot projects; ENDOGENOUS LIGAND; PEPTIDE; IDENTIFICATION;
D O I
10.23736/S1121-421X.19.02602-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Urotensin II (U-II) is a vasoactive peptide that interacts with a specific receptor named UTR. Recently, our group has demonstrated increased UTR expression in both human colon adenocarcinoma cell lines and adenomatous polyps, as well as in colon carcinoma samples if compared to healthy colon samples of the same patients. We also showed that an UTR agonist induced an increase in colon adenocarcinoma cell growth in vitro, whereas the UTR block with a specific antagonist caused an inhibition of their growth and an inhibition of about 50% of both motility and cell invasion. Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) associated with an increased baseline risk for colon cancer compared with the general population, and this risk is mostly attributed to chronic inflammation and immune dysregulation. This risk increases along with the duration of the disease, as demonstrated by many studies. There are no UTR expression data related to UC, and we therefore evaluated UTR expression in ill colon biopsies and in healthy colon ones of patients with UC and colon biopsies of healthy patients. METHODS: We enrolled, prior to informed consent, 11 patients (5 males and 6 females, age range 29-75 years, median age 52,,ears) with first UC diagnosis compared to 11 healthy controls (6 males and 5 females, age range 30-78 years, median age 55 years). We have therefore sampled inflammatory and healthy tissue in UC patients. We have also taken colic tissue samples in healthy subjects. Evaluation of receptor expression was performed by reverse transcription-polymerase chain reaction (RT-PCR), Western Blot analysis. The ANOVA Test (P<0.05) was used for statistical analysis. RESULTS: We found: 1) increased expression of UTR in 11/11 UC patients with ill mucosa biopsies compared to healthy controls in RT-PCR and in Western Blot analysis; 2) increased UTR expression in 11/11 UC patients with ill colon biopsies compared to the results obtained from healthy colon biopsies of the same patients both in RT-PCR and in Western Blot analysis; 3) increased UTR expression in 9/11 UC patients healthy colon biopsy specimens compared to healthy controls. CONCLUSIONS: UTR could be considered as an inflammatory UC disease marker because its expression is greater in the mucosa of ill colon than in the healthy colon of the same patients and compared to healthy controls.
引用
收藏
页码:23 / 28
页数:6
相关论文
共 50 条
  • [21] Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy
    Dai, Hong-Yan
    Guo, Xin-Gui
    Ge, Zhi-Ming
    Li, Zhen-Hua
    Yu, Xiao-Jing
    Tang, Meng-Xiong
    Zhang, Yun
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2008, 22 (02) : 137 - 143
  • [22] Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II
    Takahashi, K
    Totsune, K
    Murakami, O
    Arihara, Z
    Noshiro, T
    Hayashi, Y
    Shibahara, S
    PEPTIDES, 2003, 24 (02) : 301 - 306
  • [23] A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects
    Hunt, Benjamin D.
    Ng, Leong L.
    Lambert, David G.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2010, 382 (01) : 1 - 31
  • [24] A study on expression levels of matrix metalloproteinases and their inhibitors in patients with ulcerative colitis
    Huang, Guo-Dong
    Xiong, Jing
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 15 (11) : 2351 - 2356
  • [25] A study on the expression levels of matrix metalloproteinases and their inhibitors in patients with ulcerative colitis
    Huang, Guo-Dong
    Xiong, Jing
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2017, 16 (02) : 439 - 443
  • [26] Probiotics in spondyloarthropathy associated with ulcerative colitis: a pilot study
    Sanges, M.
    Valente, G.
    Rea, M.
    Della Gatta, R.
    De Franchis, G.
    Sollazzo, R.
    D'Arienzo, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2009, 13 (03) : 233 - 234
  • [27] Serum antioxidant levels in ulcerative colitis - A pilot study
    Ragunath, K
    Lloyd, D
    Mani, V
    GASTROENTEROLOGY, 1996, 110 (04) : A997 - A997
  • [28] Intravenous azathioprine in severe ulcerative colitis: A pilot study
    Mahadevan, U
    Tremaine, WJ
    Johnson, T
    Pike, MG
    Mays, DC
    Lipsky, JJ
    Sandborn, WJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (12): : 3463 - 3468
  • [29] Nicotine enemas for active ulcerative colitis - a pilot study
    Green, JT
    Thomas, GAO
    Rhodes, J
    Williams, GT
    Evans, BK
    Russell, MAH
    Feyerabend, C
    Rhodes, P
    Sandborn, WJ
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (05) : 859 - 863
  • [30] Lignocaine carbomer enemas for ulcerative colitis: A pilot study
    Green, JT
    Evans, BK
    Rhodes, J
    Thomas, GAO
    Williams, GT
    GUT, 1997, 41 : A224 - A225